HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, March 12, 2019 (HealthDay News) -- The risk of stillbirth is increased in women with intrahepatic cholestasis of pregnancy when serum bile acids concentrations are ≥100 µmol/L or more, according to a review published in the March 2 issue of The Lancet.
Caroline Ovadia, from King's College London, and colleagues conducted a systematic literature review to identify studies defining intrahepatic cholestasis of pregnancy based upon pruritus and elevated serum bile acid concentrations, with or without raised liver aminotransferase concentrations. The goal was to determine whether elevated bile acid concentrations were associated with the risk of stillbirth and preterm birth based on 23 studies eligible for the aggregate data meta-analysis (5,557 intrahepatic cholestasis of pregnancy cases and 165,136 controls) and 27 studies with individual patient data (5,269 intrahepatic cholestasis of pregnancy cases).
The researchers found that stillbirth occurred in 0.83 percent of 4,936 intrahepatic cholestasis of pregnancy cases and in 0.32 percent of 163,947 control pregnancies (odds ratio [OR], 1.46; 95 percent confidence interval, 0.73 to 2.89). Maximum total bile acid concentration was associated with stillbirth (area under the receiver operating characteristic curve [ROC AUC], 0.83), but alanine aminotransferase was not associated with stillbirth in singleton pregnancies (ROC AUC, 0.46). Compared to women with serum total bile acids of <40 µmol/L, the prevalence of stillbirth was higher in those with bile acids ≥100 µmol/L (hazard ratio [HR], 30.5; 95 percent confidence interval, 8.83 to 105.3; P < 0.0001).
"Because most women with intrahepatic cholestasis of pregnancy have bile acids below this concentration, they can probably be reassured that the risk of stillbirth is similar to that of pregnant women in the general population, provided repeat bile acid testing is done until delivery," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 27, 2022